Melyssa Bratton, Manager Biospecimen Core Research Laboratory and Research Laboratory Manager at Ochsner Health, shared on LinkedIn:
“More than 20 years ago, my family and I moved to New Orleans, and that decision helped shape my passion for triple-negative breast cancer (TNBC) research.
TNBC disproportionately impacts Black women, who are diagnosed at nearly twice the rate of White women, and states across the Southeast, including Louisiana and Mississippi, continue to experience some of the highest TNBC incidence rates in the country.
Addressing those disparities is one of the reasons I wrote the grant that was recently funded. I’m driven by a desire to better understand why outcomes differ and how we can close those gaps.
I’m especially fascinated by the intersection of tumor biology, genetics, and treatment response. Understanding how genomic alterations influence outcomes, and whether those relationships differ across patient populations has become a major focus of my work.
If you’re conducting research in this area, I invite you to consider submitting to the upcoming Cancers Special Issue on Genomic Instability and Cancer. I’m excited to help showcase innovative work that advances our understanding of cancer biology and improves outcomes for patients.”
You can also read:
FDA Approvals for Metastatic TNBC: 2 New Options Explained
